Back to search results

Oral Tranexamic Acid for Total Shoulder Arthroplasty Recovery

This study is looking at whether taking oral tranexamic acid after total shoulder arthroplasty (shoulder replacement surgery) can improve short-term recovery. Half of the participants will receive oral tranexamic acid, and the other half will receive a placebo (an inactive pill). Researchers want to see if tranexamic acid helps reduce pain, which will be measured using a VAS (Visual Analog Scale) at 2 weeks after surgery. You may be able to join if you are between 18 and 79 years old and are having your first total shoulder arthroplasty. However, you cannot participate if you have certain health conditions like cancer, heart disease, or if you are pregnant or breastfeeding. The study plans to enroll 60 people, and its current status is unclear.

Study design
This is an interventional study where participants will be randomly assigned to receive either oral tranexamic acid or a placebo. It aims to enroll 60 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your pain will be measured at 2 weeks after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06902714

Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty

Recruiting
PHASE3Ages 18–79InterventionalTreatment
University of Alabama at Birmingham
~60 participants
Updated 2026-04-28 on ClinicalTrials.gov
What's tested:oral tranexamic acidPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
VAS
Measured over 2 weeks

Conditions

Shoulder Arthroplasty

Explore related trials

Arthroplasty of shoulder

NCT06902714

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Alabama at Birmingham

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Walter Smith, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Walter Smith
[email protected]
205-930-8554
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Skeletally mature patients (ages 18-79) undergoing primary total shoulder arthroplasty

Exclusion

Patients with Cancer, venous thromboembolism, stroke, heart disease, pregnant or nursing, allergic to TXA, current tobacco use, anticoagulants other than aspirin.

What this trial measures

  • VAS2 weeks

    visual analog scale